Immunogenicity of an HPV-16 L2 DNA vaccine

Vaccine

Volumn 27, Issue 46, 2009, Pages 6432-6434

  Hitzeroth, Inga I ^a,b   Passmore, Jo Ann S ^a   Shephard, Enid ^c   Stewart, Debbie ^a   Müller, Martin ^d   Williamson, Anna Lise ^a,e   Rybicki, Edward P ^a,b   Kast, W Martin ^f,g  

^a Institute of Infectious Disease and Molecular Medicine   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

1.2 protein; DNA vaccine; Human papillomavirus; Immunogenicity

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L2; DNA VACCINE; HPV 16 L2 DNA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR VOLUME; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE, TUMOR; FEMALE; HUMAN PAPILLOMAVIRUS 16; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, DNA;

EID: 70350141305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.015     Document Type: Article

References (12)

1. Maclean J., Rybicki E.P., and Williamson A.L. Vaccination strategies for the prevention of cervical cancer. Expert Reviews Anticancer Therapy 5 (2005) 97-107
2. Kawana K., Yasugi T., Kanda T., Kino N., Oda K., Okada S., et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21 (2003) 4256-4260
3. Hung C.-F., Monie A., Alvarez R.D., and Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Experimental and Molecular Medicine 39 (2007) 679-689
4. Kim D., Garnbhira R., Karanam B., Monie A., Hung C.F., Roden R., and Wu T.C. Generation and characterization of a preventative and therapeutic HPV DNA vaccine. Vaccine 26 (2008) 351-360
5. Hanke T., Schneider J., Gilbert S.C., Hill A.V., and McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16 (1998) 426-435
6. De Bruijn M.L., Greenstone H.I., Veryneulen H., Melief C.J., Lowy D.R., Schiller J.T., et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250 (1998) 371-376
7. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., and Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. Journal of Virology 77 (2003) 8386-8393
8. Leder C., Kleinschmidt J.A., Wiethe C., and Muller M. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. Journal of Virology 75 (2001) 9201-9209
9. Pastrana D.V., Buck G.B., Pang V.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 (2004) 205-216
10. Gambhira R., Gravitt P.E., Bossis I., Stern P.L., Viscidi R.P., and Roden R. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Research 66 (2006) 11120-11124
11. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.V., Thompson C.D., Cuip T.O., et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 (2005) 365-372
12. Garnbhira R., Jagu S., Karanam B., Gravitt P.E., Gulp T.O., Christensen N.O., et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. Journal of Virology 81 (2007) 11585-11592